Effects of CYP2D6 activity and tobacco on larynx cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 5, Issue 9, 1996, Pages 683-686

  Benhamou, Simone ^a   Bouchardy, Christine ^b   Paoletti, Catherine ^a   Dayer, Pierre ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b GENEVA CANCER REGISTRY   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME;

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; TOBACCO;

AGED; CARCINOGENS; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; LARYNGEAL NEOPLASMS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; PLANTS, TOXIC; RISK FACTORS; SINGLE-BLIND METHOD; SMOKING; TOBACCO;

EID: 0029788010     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Gonzalez, F. J., and Idle, J. R. Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin. Pharmacokinet., 26: 59-70, 1994.
2. Crespi, C. L., Penman, B. W., Gelboin, H. V., and Gonzalez, F. J. A tobacco smoked-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis (Lond.), 12: 1197-1201, 1991.
3. Bouchardy, C., Benhamou, S., and Dayer, P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res., 56: 251-253, 1996.
4. IARC. Tobacco Smoking. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. IARC Sci. Publ., 38: 270-303, 1986.
5. Dayer, P., Leeman, T., and Striberni, R. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 dbl activity. Clin. Pharmacol. & Ther., 45: 34-40, 1989.
6. WHO. International Classification of Diseases for Oncology. Geneva, Switzerland: WHO, pp. 6-7, 1976.
7. Breslow, N. E., and Day, N. E. Statistical Methods in Cancer Research. I. The Analysis of Case-Control Studies. IARC Scientific Publications. IARC Scientific Publ. No. 32, pp. 192-242. Lyon, France: IARC, 1980.
8. Baker, R. J., and Neider, J. A. Generalized Linear Interactive Modelling (GLIM) System. Release 3. Oxford: Numerical Algorithms Group, 1978.
9. IARC. Tobacco Smoking. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. IARC Sci. Publ., 38: 55, 1986.
10. Péquignot, G., Crosignani, P., Terracini, B., Ascunce, N., Zubiri, A., Raymond, L., Estève, J., and Tuyns, A. J. A comparative study of smoking, drinking and dietary habits in population samples in France, Italy, Spain, and Switzerland. III. Consumption of alcohol. Rev. Epidémiol. Santé Pub., 36: 177-185, 1988.
11. Jacqz, E., Dulac, H., and Mathieu, H. Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur. J. Clin. Pharmacol., 35: 167-171, 1988.
12. Smith, T. J., Guo, Z., Gonzalez, F. J., Guengerich, F. P., Stoner, G. D., and Yang C. S. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res., 52: 1757-1763, 1992.
13. Penman, B. W., Reece, J., Smith, T., Yang, C. S., Gelboin, H. V., Gonzalez, F. J., and Crespi, C. L. Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics, 3: 28-39, 1993.
14. Cholerton, S., Arpanahi, A., McCracken, N., Boustead, C., Taber, H., Johnstone, E., Leathart, J., Daly, A. K., and Idle, J. R. Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet, 343: 62-63, 1994.
15. Yang, C. S., Smith, T. J., Hong, J. H., and Zhou, S. Kinetics and enzymes involved in the metabolism of nitrosamines. In: R. N. Loeppky and C. J. Michejda (eds.), The Chemistry and Biochemistry of Nitrosamines and Related N-Nitroso Compounds, pp. 169-178. American Chemical Society Symposium, Series 553. Washington DC: American Chemical Society, 1994.
16. Degawa, M., Stern, S. J., Martin, M. V., Guengerich, P., Fu, P. P., Ilett, K. F., Kaderlik, R. K., and Kadlubar, F. F. Metabolic activation and carcinogen-DNA adduct detection in human larynx. Cancer Res., 54: 4915-4919, 1994.
17. Guengerich, F. P., Kim, D. H., and Iwasaki, M. Role of human cytochrome P-450IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol., 4: 168-179, 1991.
18. Dayer, P. Advantages and drawbacks of probe drugs for the assessment of phenotypic expression of cytochrome P450db1 (P450D6). In: G. Alvan, L. P. Balant, P. R. Bechtel, A. R. Boobis, L. F. Gram, and K. Pithan (eds.), European Cooperation in the Field of Scientific and Technical Research: European Consensus Conference on Pharmacogenetics, Besançon, pp. 33-42. Brussels: Commission of the European Community, 1989.
19. Schmid, B., Bircher, J., Preisig, R., and Küpfer, A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin. Pharmacol. Ther., 38: 618-624, 1995.
20. Roots, I., Drakoulis, N., and Brockmöller, J. Polymorphic enzymes and cancer risk: concepts, methodology and data review. In: W. Kalow (ed.), Pharmacogenetics of Drug Metabolism, pp. 815-841, New York: Pergamon Press, 1992.